Ticker
AEZS

Price
5.30
Stock movement up
+0.02 (0.38%)
Company name
Aeterna Zentaris Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
25.74M
Ent value
-14.67M
Price/Sales
4.16
Price/Book
0.48
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-69.28%
3 year return
-53.29%
5 year return
-35.57%
10 year return
-50.97%
Last updated: 2022-08-25

DIVIDENDS

AEZS does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.16
Price to Book0.48
EV to Sales-2.37

FINANCIALS

Per share

Loading...
Per share data
Current share count4.86M
EPS (TTM)-1.97
FCF per share (TTM)-1.88

Income statement

Loading...
Income statement data
Revenue (TTM)6.19M
Gross profit (TTM)6.05M
Operating income (TTM)-10.17M
Net income (TTM)-9.56M
EPS (TTM)-1.97
EPS (1y forward)-2.50

Margins

Loading...
Margins data
Gross margin (TTM)97.74%
Operating margin (TTM)-164.24%
Profit margin (TTM)-154.47%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash63.60M
Net receivables2.17M
Total current assets67.10M
Goodwill7.98M
Intangible assets612.00K
Property, plant and equipment0.00
Total assets76.34M
Accounts payable1.02M
Short/Current long term debt165.00K
Total current liabilities5.67M
Total liabilities23.18M
Shareholder's equity53.16M
Net tangible assets44.57M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-9.00M
Capital expenditures (TTM)138.00K
Free cash flow (TTM)-9.13M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-17.99%
Return on Assets-12.53%
Return on Invested Capital-17.99%
Cash Return on Invested Capital-17.18%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.30
Daily high5.39
Daily low5.24
Daily Volume49K
All-time high94881.00
1y analyst estimate37.50
Beta1.71
EPS (TTM)-1.97
Dividend per share-
Ex-div date-
Next earnings date2 Nov 2022

Downside potential

Loading...
Downside potential data
AEZSS&P500
Current price drop from All-time high-99.99%-13.41%
Highest price drop-100.00%-56.47%
Date of highest drop15 Jun 20229 Mar 2009
Avg drop from high-79.25%-11.38%
Avg time to new high918 days12 days
Max time to new high5486 days1805 days
COMPANY DETAILS
AEZS (Aeterna Zentaris Inc) company logo
Marketcap
25.74M
Marketcap category
Small-cap
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Employees
0
Investor relations
-
SEC filings
CEO
Klaus Paulini
Country
USA
City
Charleston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 stud...
August 29, 2022
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -...
August 3, 2022
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
July 28, 2022
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing thera...
July 18, 2022
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
July 15, 2022
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
July 6, 2022
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a spe...
June 21, 2022
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th Intern...
June 13, 2022
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
June 9, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
June 3, 2022
Next page